Zacks Investment Research on MSN4h
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key InsightsThe most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...
BofA notes press reports that the Trump administration is allegedly considering cutting HIV prevention activities from the CDC budget and that ...
Nvidia stock rises after the chip maker makes a number of product announcements at its annual AI GTC conference, Tesla trades ...
The S&P 500 added 1.1% on Wednesday, March 19, 2025, as the Fed held interest rates steady, reaffirming plans for future cuts ...
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
GlobalData on MSN8d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
With cancer diagnoses and death rates in Michigan often higher than the national average, a new, patient-centered ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback